

# Fiscal Note 2027 Biennium

Bill#/Title:	SB0422.02 (002 cancer	2): Generally revise	laws relating	to insurance cover	rage relating to
Primary Sponsor:	Ellie Boldman		Status:	As Amended in Ser	nate
☐ Included in the Ex	ecutive Budget	☐ Needs to be included	in HB 2	☐ Significant Local Go	ov Impact
☐ Significant Long-Term Impacts		☐ Technical Concerns ☐ Dedicated Revenue Form		Form Attached	
		FISCAL SU	MMARY		
		FY 2026 Difference	FY 2027 Difference	FY 2028 Difference	FY 2029 Difference
Expenditures					
Other		\$0	\$0	\$0	\$0
Proprietary Fun	d	\$980,267	\$1,024,083	\$1,070,078	\$1,118,369
Revenues					
Other		\$0	\$0	\$0	\$0
Net Impact			\$0		\$0

## Description of fiscal impact

General Fund Balance

SB 422, as amended, requires health insurance coverage related to advanced metastatic cancer and prohibits insurers from requiring prior drug failure or proof of a history of failure of a different drug. Additionally, the bill mandates coverage for associated conditions and the side effects of cancer treatment. There is a fiscal impact to the State Health Benefit Plan and the Montana University System Group Insurance Plan from this proposed legislation.

The effect of this legislation, in combination with other legislation that requires certain benefit coverage, may over time require increases to employee contributions or the state share as set by 2-18-703, MCA, or both.

#### FISCAL ANALYSIS

#### Assumptions

#### **Commissioner of Higher Education**

- 1. This bill, as amended, will have a fiscal impact on the Montana University System's Group Insurance Plan based on the following assumptions:
  - a. Annual average of plan cost of cancer therapy drugs is \$4,096,650.
  - b. Adjustment for claims incurred but not reported (IBNR) is 1.002.
  - c. Estimated claims trend from midpoint to FY 2026 is 1.170.
  - d. Estimated FY 2026 plan cost of cancer therapy drugs (a x b x c) is \$4,802,667.
  - e. Expected unit cost increase due to bill language is 10%.
  - f. Estimated additional plan cost of cancer therapy drugs under bill (d x e) is \$480,267.

g. A trend inflation factor of 6% was applied for FY 2027, FY 2028, and FY 2029.

# Department of Administration

- 2. From Navitus' perspective, as the pharmacy benefit manager for the State Health Benefit Plan, the company generally does not have a strong preference for specific oncology medications over others. However, an exception for advanced prostate cancer does exist if the usage of Abiraterone (generic agent) is bypassed for the branded agents like Nubeqa, Erleada, and Xtandi, where the monthly costs are extreme.
- 3. Abiraterone (generic agent) monthly costs range from \$200 to \$250.
- 4. Nubeqa/Erleada/Xtandi (branded agents) monthly costs range from \$11,000 to \$14,000.
- 5. Based on recent State Health Benefit Plan utilization trends, if all applicable claims had been for a branded agent, the additional cost would be approximately \$500,000.
- 6. An inflation factor of 3% was applied for FY 2027, FY 2028, and FY 2029.

# Department of Public Health and Human Services

7. The amendment to SB 422 does not include or apply to the Medicaid/CHIP programs. The amendment is specific to Title 33, insurance and insurance companies. There will be no fiscal impact to the department.

#### **State Auditor's Office**

8. The requirements of SB 422, as amended, could cause an increase in enforcement on the part of the State Auditor's Office. However, the office will absorb the additional enforcement activities with existing staff.

## Fiscal Analysis Table

		<u> </u>		
<b>Commissioner of Higher Educatio</b>	n			
	FY 2026 Difference	FY 2027 Difference	FY 2028 Difference	FY 2029 Difference
Fiscal Impact				
Expenditures Benefits	\$480,267	\$509,083	\$539,628	\$572,005
TOTAL Expenditures	\$480,267	\$509,083	\$539,628	\$572,005
Funding of Expenditures Other Proprietary Fund TOTAL Funding of Expenditures	\$0 \$480,267 <b>\$480,267</b>	\$0 \$509,083 <b>\$509,083</b>	\$0 \$539,628 <b>\$539,628</b>	\$0 \$572,005 <b>\$572,005</b>
Revenues Not Impact to Fund Polones (Paus	Eundine	of Eumanditumas)		
Net Impact to Fund Balance (Reve Other	enue minus Funding \$0	g of Expenditures) \$0	\$0	\$0
Proprietary Fund	(\$480,267)	(\$509,083)	(\$539,628)	(\$572,005)
Department of Administration				
	FY 2026 Difference	FY 2027 Difference	FY 2028 Difference	FY 2029 Difference
Fiscal Impact				
Expenditures Benefits	\$500,000	\$515,000	\$530,450	\$546,364
TOTAL Expenditures	\$500,000	\$515,000	\$530,450	\$546,364
Funding of Expenditures Other Proprietary Fund	\$0 \$500,000	\$0 \$515,000	\$0 \$530,450	\$0 \$546,364

Fiscal Note Request - As Amende	ed in Senate			(continued)
TOTAL Funding of Expenditures	\$500,000	\$515,000	\$530,450	\$546,364
Revenues				
Net Impact to Fund Balance (Re	venue minus Funding	of Expenditures)		
Other	\$0	\$0	\$0	\$0
Proprietary Fund	(\$500,000)	(\$515,000)	(\$530,450)	(\$546,364)
STATEWIDE SUMMARY				
	FY 2026	FY 2027	FY 2028	FY 2029
	<b>Difference</b>	<b>Difference</b>	<b>Difference</b>	<b>Difference</b>
Fiscal Impact				
TOTAL Fiscal Impact	0.00	0.00	0.00	0.00
Expenditures				
Benefits	\$980,267	\$1,024,083	\$1,070,078	\$1,118,369
TOTAL Expenditures	\$980,267	\$1,024,083	\$1,070,078	\$1,118,369
Funding of Expenditures				
Other	\$0	\$0	\$0	\$0
Proprietary Fund	\$980,267	\$1,024,083	\$1,070,078	\$1,118,369
TOTAL Funding of	\$980,267	\$1,024,083	\$1,070,078	\$1,118,369
Expenditures	( <del></del>	-		
Revenues				
TOTAL Revenues	<u> </u>	<u>\$0</u>		\$0
Net Impact to Fund Balance (Re	57.0 0.1 0.5			
Other	\$0	\$0	\$0	\$0

# Effect on County or Other Local Revenues or Expenditures Montana Association of Counties

1. The Montana Association of Counties assumes this coverage will not dramatically increase county health insurance premiums.

NO SPONSOR SIGNATURE		00		
		100	3/26/2025	
Sponsor's Initials	Date	Budget Director's Initials	Date	

Proprietary Fund